Loading…
* Free cash flow = OCF − net investing outflow (the filings carry no standalone capex line).
Operates in Healthcare Services. Per the activity note to the FY2024 annual report, the company operates as a clinical research organization conducting trials and studies globally.
Subsidiary of Shezghuduli Pasukhismgeblobis Sazogadoeba Pareksel International Holding Bi.vi. (100.0%)
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | CAGR |
|---|---|---|---|---|---|---|---|
| Total Revenue | 3,857 | 3,222 | 5,211 | 6,567 | 9,074 | 10,296 | +21.7% |
| Total COGS | 0 | 0 | 0 | 0 | 0 | 0 | |
| Gross Profit | 3,857 | 3,222 | 5,211 | 6,567 | 9,074 | 10,296 | +21.7% |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 2,884 | 3,066 | 4,663 | 6,018 | 8,589 | 9,522 | +27.0% | |
| EBITDA | 973 | 155 | 549 | 548 | 485 | 774 | -4.5% |
| EBITDA Margin | 25.2% | 4.8% | 10.5% | 8.3% | 5.3% | 7.5% | |
| Total D&A | 122 | 136 | 139 | 131 | 106 | 143 | +3.2% |
| EBIT / Operating Income | 851 | 20 | 410 | 417 | 379 | 631 | -5.8% |
| 4 | 69 | 115 | 370 | 320 | 9 | nmf | |
| Profit Before Tax | 847 | 89 | 295 | 47 | 699 | 640 | -5.4% |
| Total Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | |
| Net Profit / (Loss) | 847 | 215 | 293 | 47 | 699 | 640 | -5.4% |
| Net Margin | 22.0% | 6.7% | 5.6% | 0.7% | 7.7% | 6.2% |
Shareholders, directors and group links from the companyinfo.ge public register — as filed, so stakes need not sum to 100% where a holding is undisclosed.
Ownership & directors from companyinfo.ge (public corporate registry).
Ranked by how close each latest revenue is to this one — not a curated comp set. Open this set in Compare →